SCHEMBL30980502

SCHEMBL30980502

CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1CCCCCCN

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.51
▸ ALDH1A1 P00352 2/20 0.47
▸ THRB P10828 1/20 0.47
▸ LGALS8 O00214 1/20 0.41
▸ LGALS3 P17931 1/20 0.41
▸ LGALS4 P56470 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ CD69 Q07108 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21947408 0.88 MAPK1 (0.65) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL6942761 0.88 MAPK1 (0.65) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL6944012 0.88 MAPK1 (0.65) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL3296000 0.88 MAPK1 (0.65) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL3295994 0.88 MAPK1 (0.65) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL23478019 0.88 MAPK1 (0.65) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL3295282 0.88 MAPK1 (0.65) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL3295284 0.88 MAPK1 (0.65) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL21415430 0.87 MAPK1 (0.51) MAPK1ALDH1A1THRBLGALS8LGALS3
SCHEMBL31384251 0.87 MAPK1 (0.53) MAPK1ALDH1A1THRBLGALS8LGALS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
WO-2025035040-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES LYCIA THERAPEUTICS, INC. (US) 2025-02-13 — — WO disclosed
WO-2024155747-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 — — WO disclosed
Send feedback